PDF factsheet
      Z

HR-slowing agents in heart failure for all type of patients, clinical trials results

ivabradine versus placebo
SHIFT, 2010
ISRCTN70429960
ivabradine
versus
placebo
patients with NYHA class 2-4 heart failure, an LVEF <35%, a resting heart rate >70 bpm, and a heart-failure hospitalization within the previous year double-blind
Follow-up duration: 23 months
37 countries
ivabradine 15mg versus placebo
BEAUTIFUL, 2008
NCT00143507
ivabradine target dose of 7ยท5 mg twice a day
versus
placebo
patients with coronary artery disease and left-ventricular systolic dysfunction (LVEF <=40%) double blind
Follow-up duration: 19 months (range 16-24)
33 countries

  Options


in first

in second

  Filter